Skip to main content

Advertisement

SpringerLink
Log in

Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Diffuse large B cell lymphoma (DLBCL) patients carrying hepatitis C virus (HCV) have higher risk of treatment toxicity and complications. The aim of this study was to assess the impact of HCV in a series of DLBCL patients treated with immunochemotherapy. 321 patients (161 M/160F; median age, 66 years) diagnosed with de novo DLBCL in a single center between 2002 and 2013 were included. Immunodeficiency-related lymphomas were excluded. HCV+ cases were defined by the presence of IgG anti-HCV. Main clinico-biological characteristics and outcome were analyzed according to the viral status. Two hundred ninety patients were HCV− and 31 HCV+. HCV+ patients were older (median age 71 vs. 64 years, P = 0.03), had more often B symptoms (P = 0.013), spleen (P = 0.003), and liver (P = 0.011) involvement, higher rate of early death (<4 months, P = .001), and shorter overall survival (OS). Eleven HCV+ patients had cirrhosis criteria. HCV+ patients with impaired liver function before or during treatment showed inferior OS. Elevated pre-treatment bilirubin correlated also with higher liver toxicity. In a multivariate analysis that included R-IPI score, serum beta2-microglobulin (β2m), HCV status, and presence of cirrhosis, only R-IPI, β2m, and cirrhosis showed independent prognostic impact on OS. The presence of HCV in DLBCL patients entails higher number of complications and early deaths; however, liver impairment and not the hepatitis viral status was the key feature in the outcome of the patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 89:3909–3918.

  2. Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 116:2040–2045

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Garcia-Fulgueiras A, Tormo MJ, Rodriguez T et al (1996) Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2, 203 adults. Scand J Infect Dis 28:17–20

    Article  CAS  PubMed  Google Scholar 

  4. de Sanjose S, Benavente Y, Vajdic CM et al (2008) Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol 6:451–458

    Article  PubMed  PubMed Central  Google Scholar 

  5. Besson C, Canioni D, Lepage E et al (2006) Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte programs. J Clin Oncol 24:953–960

    Article  PubMed  Google Scholar 

  6. Visco C, Arcaini L, Brusamolino E et al (2006) Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 17:1434–1440

    Article  CAS  PubMed  Google Scholar 

  7. Arcaini L, Rossi D, Lucioni M et al (2015) The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. Haematologica 100:246–252

    Article  PubMed  PubMed Central  Google Scholar 

  8. Nishikawa H, Tsudo M, Osaki Y (2012) Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience. Oncol Rep 28:835–840

    CAS  PubMed  Google Scholar 

  9. Chen TT, Chiu CF, Yang TY et al (2015) Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy. Leuk Res 39:151–156

    Article  CAS  PubMed  Google Scholar 

  10. Ennishi D, Maeda Y, Niitsu N et al (2010) Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 116:5119–5125

    Article  CAS  PubMed  Google Scholar 

  11. Sehn LH, Berry B, Chhanabhai M et al (2007) The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857–1861

    Article  CAS  PubMed  Google Scholar 

  12. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol 17:1244

    CAS  PubMed  Google Scholar 

  13. Merli M, Visco C, Spina M et al (2014) Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 99:489–496

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Alonso Lopez S, Agudo Fernandez S, Garcia Del Val A, et al. [Hepatitis C seroprevalence in an at-risk population in the southwest Madrid region of Spain]. Gastroenterol Hepatol 2016.

  15. Pellicelli AM, Marignani M, Zoli V et al (2011) Hepatitis C virus-related B cell subtypes in non Hodgkin’s lymphoma. World J Hepatol 3:278–284

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hosry J, Mahale P, Turturro F, et al. (2016) Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. Int J Cancer.

  17. Michot JM, Canioni D, Driss H et al (2015) Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol 90:197–203

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by the Instituto de Salud Carlos III, Spanish Ministry of Health (PI12/01536 and PIE1313/00033); Red Temática de Investigación Cooperativa en Cáncer (RTICC, RD12/0036/0023), all co-founded by the European Regional Development Fund (FEDER); by Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2014 SGR 668), Generalitat de Catalunya, and by the “Josep Font” grant from Hospital Clinic Barcelona.

Author information

Authors and Affiliations

  1. Department of Hematology, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain

    Ivan Dlouhy, Miguel Á. Torrente, Jordina Rovira, Laura Magnano, Eva Giné, Julio Delgado & Armando López-Guillermo

  2. Department of Hepatology, Hospital Clínic, Barcelona, Spain

    Sabela Lens, Xavier Forns & José M. Sánchez-Tapias

  3. Department of Pathology, Hospital Clínic, Barcelona, Spain

    Olga Balagué, Antonio Martínez & Elías Campo

  4. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

    Elías Campo & Armando López-Guillermo

Authors
  1. Ivan Dlouhy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miguel Á. Torrente
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sabela Lens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jordina Rovira
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laura Magnano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eva Giné
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Julio Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Olga Balagué
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Antonio Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Elías Campo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xavier Forns
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. José M. Sánchez-Tapias
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Armando López-Guillermo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivan Dlouhy.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Ivan Dlouhy and Miguel Á. Torrente equally contributed to this manuscript

Electronic supplementary material

Supplementary Fig 1

Progression-free survival (PFS) and overall survival (OS) of the overall cohort with diffuse large B-cell lymphoma (TIFF 96 kb)

High resolution image (GIF 15 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dlouhy, I., Torrente, M.Á., Lens, S. et al. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Ann Hematol 96, 405–410 (2017). https://doi.org/10.1007/s00277-016-2903-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2903-8

Keywords

Search

Navigation